JPWO2022159976A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022159976A5 JPWO2022159976A5 JP2023544070A JP2023544070A JPWO2022159976A5 JP WO2022159976 A5 JPWO2022159976 A5 JP WO2022159976A5 JP 2023544070 A JP2023544070 A JP 2023544070A JP 2023544070 A JP2023544070 A JP 2023544070A JP WO2022159976 A5 JPWO2022159976 A5 JP WO2022159976A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- sulfur
- independently
- oxygen
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 53
- 150000001875 compounds Chemical class 0.000 claims description 41
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 36
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 36
- 125000005842 heteroatom Chemical group 0.000 claims description 36
- 229910052757 nitrogen Inorganic materials 0.000 claims description 36
- 229910052760 oxygen Inorganic materials 0.000 claims description 36
- 239000001301 oxygen Substances 0.000 claims description 36
- 229920006395 saturated elastomer Polymers 0.000 claims description 36
- 229910052717 sulfur Inorganic materials 0.000 claims description 36
- 239000011593 sulfur Substances 0.000 claims description 36
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 125000001931 aliphatic group Chemical group 0.000 claims description 12
- 125000004429 atom Chemical group 0.000 claims description 12
- 125000001620 monocyclic carbocycle group Chemical group 0.000 claims description 9
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 7
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 7
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims description 7
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000005549 heteroarylene group Chemical group 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 201000010099 disease Diseases 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 description 4
- 208000002814 Autosomal Recessive Polycystic Kidney Diseases 0.000 description 4
- 208000017354 Autosomal recessive polycystic kidney disease Diseases 0.000 description 4
- 206010070666 Cortical dysplasia Diseases 0.000 description 4
- 208000026437 Familial focal epilepsy with variable foci Diseases 0.000 description 4
- 208000001914 Fragile X syndrome Diseases 0.000 description 4
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 4
- 208000006289 Rett Syndrome Diseases 0.000 description 4
- 206010064930 age-related macular degeneration Diseases 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 description 4
- 230000037416 cystogenesis Effects 0.000 description 4
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 4
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 4
- 208000003119 hemimegalencephaly Diseases 0.000 description 4
- 208000002780 macular degeneration Diseases 0.000 description 4
- 201000008914 temporal lobe epilepsy Diseases 0.000 description 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 201000011190 diabetic macular edema Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000037417 hyperactivation Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 208000026585 laminopathy Diseases 0.000 description 2
- 201000009925 nephrosclerosis Diseases 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163140523P | 2021-01-22 | 2021-01-22 | |
| US63/140,523 | 2021-01-22 | ||
| US202163202524P | 2021-06-15 | 2021-06-15 | |
| US63/202,524 | 2021-06-15 | ||
| PCT/US2022/070308 WO2022159976A1 (en) | 2021-01-22 | 2022-01-24 | Rapamycin analogs and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024503898A JP2024503898A (ja) | 2024-01-29 |
| JP2024503898A5 JP2024503898A5 (https=) | 2025-02-03 |
| JPWO2022159976A5 true JPWO2022159976A5 (https=) | 2025-02-03 |
Family
ID=82549982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023544070A Pending JP2024503898A (ja) | 2021-01-22 | 2022-01-24 | ラパマイシン類似体及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220267352A1 (https=) |
| EP (1) | EP4281463A4 (https=) |
| JP (1) | JP2024503898A (https=) |
| KR (1) | KR20230136625A (https=) |
| AU (1) | AU2022209863A1 (https=) |
| BR (1) | BR112023014287A2 (https=) |
| CA (1) | CA3209086A1 (https=) |
| MX (1) | MX2023008634A (https=) |
| WO (1) | WO2022159976A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3914245A4 (en) | 2019-01-22 | 2022-08-24 | Aeovian Pharmaceuticals, Inc. | MTORC-1 MODULATORS AND USES THEREOF |
| WO2021195599A1 (en) | 2020-03-27 | 2021-09-30 | Aeovian Pharmaceuticals, Inc. | Mtorc1 modulators and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA935110B (en) * | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
| JP2010500286A (ja) * | 2006-07-25 | 2010-01-07 | アボット・ラボラトリーズ | 結晶形態のラパマイシン類似体 |
| WO2011130232A1 (en) * | 2010-04-13 | 2011-10-20 | Novartis Ag | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
| EP2601201B1 (en) * | 2010-08-04 | 2014-09-24 | Meril Life Sciences Pvt. Ltd. | Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties" |
| US10683308B2 (en) * | 2015-09-11 | 2020-06-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| IL314362A (en) * | 2018-06-15 | 2024-09-01 | Janssen Pharmaceutica Nv | Rapamycin analogs and their uses |
| WO2020076738A2 (en) * | 2018-10-12 | 2020-04-16 | Bellicum Pharmaceuticals, Inc | Protein-binding compounds |
| EP3914245A4 (en) * | 2019-01-22 | 2022-08-24 | Aeovian Pharmaceuticals, Inc. | MTORC-1 MODULATORS AND USES THEREOF |
| KR20220128345A (ko) * | 2019-12-05 | 2022-09-20 | 아나쿠리아 테라퓨틱스, 인코포레이티드 | 라파마이신 유사체 및 이의 용도 |
-
2022
- 2022-01-24 JP JP2023544070A patent/JP2024503898A/ja active Pending
- 2022-01-24 CA CA3209086A patent/CA3209086A1/en active Pending
- 2022-01-24 US US17/648,750 patent/US20220267352A1/en not_active Abandoned
- 2022-01-24 AU AU2022209863A patent/AU2022209863A1/en not_active Abandoned
- 2022-01-24 MX MX2023008634A patent/MX2023008634A/es unknown
- 2022-01-24 BR BR112023014287A patent/BR112023014287A2/pt unknown
- 2022-01-24 KR KR1020237027812A patent/KR20230136625A/ko active Pending
- 2022-01-24 EP EP22743426.3A patent/EP4281463A4/en active Pending
- 2022-01-24 WO PCT/US2022/070308 patent/WO2022159976A1/en not_active Ceased